H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Vanda (VNDA – Research Report) today and set a price target of $20.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ram Selvaraju’s rating is based on Vanda’s promising long-term revenue prospects and their recent financial performance that surpassed expectations. Vanda reported revenue of $52.3 million for the full year 2024, exceeding the forecast of $49 million, and their net loss per share was slightly narrower than anticipated. The company has set a revenue guidance range of $210-250 million for 2025, with anticipated growth driven by increased uptake of Fanapt for bipolar disorder and the introduction of Ponvory. There is also potential for accelerated revenue growth in 2026 with the launches of new products like milsaperidone and imsidolimab.
Vanda’s ambitious target of reaching $1 billion in revenue by 2030 is seen as achievable, largely due to their strong neuropsychiatry-focused portfolio. The success of Fanapt in treating bipolar I disorder, along with ongoing developments such as the long-acting injectable version, bolster this outlook. Additionally, the potential approval of imsidolimab, which has completed pivotal trials, adds to the confidence in Vanda’s future prospects. These factors contribute to the reiterated Buy rating and an increased 12-month price target of $20, reflecting the positive impact of including imsidolimab in the valuation.
Selvaraju covers the Healthcare sector, focusing on stocks such as Vanda, Anavex Life Sciences, and Axsome Therapeutics. According to TipRanks, Selvaraju has an average return of 5.3% and a 40.52% success rate on recommended stocks.
In another report released on February 14, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $13.00 price target.